NoopeptvsPhenylpiracetam

Noopept modulates AMPA and NMDA receptors similarly to racetams through positive allosteric modulation. Its key distinguishing feature is upregulation of BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor) via activation of TrkB and TrkA receptor signaling cascades — these neurotrophins are essential for neuronal growth, survival, dendritic arborization, and synaptic plasticity. Noopept inhibits glutamate-induced excitotoxicity by reducing calcium influx through NMDA receptors and modulating the NR2B subunit. It activates the PI3K/Akt and MAPK/ERK pathways downstream of neurotrophin receptors. The active metabolite cycloprolylglycine (a cyclic dipeptide) has endogenous nootropic activity, potentially acting as a trace amine-associated receptor ligand. Neuroprotection is further mediated through antioxidant effects and mitochondrial stabilization.

Phenylpiracetam modulates AMPA and NMDA glutamate receptors like other racetams through positive allosteric modulation. The phenyl group confers additional affinity for dopamine (DAT) and norepinephrine (NET) transporters, acting as a weak reuptake inhibitor and increasing synaptic catecholamine availability — providing stimulatory and motivational effects. It binds to α4β2 and α7 nicotinic acetylcholine receptors as a positive allosteric modulator, enhancing cholinergic transmission in the prefrontal cortex and hippocampus. The phenyl moiety improves blood-brain barrier penetration via increased lipophilicity and potentially P-glycoprotein substrate properties. Downstream effects include enhanced CREB phosphorylation and BDNF expression. The combination of glutamatergic, dopaminergic, noradrenergic, and cholinergic modulation produces synergistic cognitive enhancement.